Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

Completed · Phase 1/Phase 2

Conditions studied: Genital Herpes Simplex Type 2

In brief

The purpose of this study is to test the safety and effectiveness of two experimental therapeutic vaccines against herpes simplex virus, type 2 (HSV-2).

Key facts

Study ID

NCT02030301

Run by

Vical

People needed

165

Starts

2013-12-01

Expected to finish

2016-02-01

Last updated by the study team

2019-02-27

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• HSV-2 seropositive
• A minimum of 1 year of reported history of genital herpes and either 2 to 9 recurrences within the year prior to screening or 2 to 9 recurrences per year prior to starting suppressive therapy

You may not qualify if…

• History of receiving an investigational HSV vaccine
• Chronic illness for which a subject's immune system is suspected to be impaired or altered, such as cancer, autoimmune conditions, or diabetes
• Pregnant or breastfeeding

Where it is running

• Alabama Vaccine Research Clinic — Birmingham, Alabama, United States
• Broward Research Group — Hollywood, Florida, United States
• Indiana University Infectious Diseases Research — Indianapolis, Indiana, United States
• Westover Heights Clinic — Portland, Oregon, United States
• Center for Clinical Studies — Houston, Texas, United States
• University of Utah - Division of Infectious Diseases — Salt Lake City, Utah, United States
• University of Washington Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.